PT  - JOURNAL ARTICLE
AU  - Van Vickle, S. Seth
AU  - Thompson, Randall C.
TI  - <sup>123</sup>I-MIBG Imaging: Patient Preparation and Technologist’s Role
AID  - 10.2967/jnmt.115.158394
DP  - 2015 Jun 01
TA  - Journal of Nuclear Medicine Technology
PG  - 82--86
VI  - 43
IP  - 2
4099  - http://tech.snmjournals.org/content/43/2/82.short
4100  - http://tech.snmjournals.org/content/43/2/82.full
SO  - J. Nucl. Med. Technol.2015 Jun 01; 43
AB  - The radiopharmaceutical 123I-metaiodobenzylguanidine (MIBG) was approved by the Food and Drug Administration in March 2013 for the assessment of myocardial sympathetic innervation in the evaluation of patients with heart failure and an ejection fraction of no more than 35%. Almost any well-equipped nuclear medicine or nuclear cardiology laboratory can perform this test, although there is a need for special attention to patient preparation, dose calibration, and proper timing of the image acquisition. This article reviews the role of the nuclear medicine technologist and some practical aspects of cardiac sympathetic 123I-MIBG imaging of which the laboratory team needs to be mindful.